Đăng xuất
Partial seizures with or without secondary generalisation
Adult: Monotherapy: Initially, 50 mg bid, increased to 100 mg bid after 1 week. Alternatively, initial doses of 100 mg bid may be given. Increase doses in increments of 50 mg bid at weekly intervals depending on patient response and tolerability. Max: 300 mg bid. Adjunctive therapy: Initially, 50 mg bid, increased to 100 mg bid after 1 week. Maintenance dose may be further increased in increments of 50 mg bid at weekly intervals depending on patient response and tolerability. Max: 200 mg bid. Treatment initiation with a loading dose: Initially, 200 mg as a single dose, followed by 100 mg bid after approx 12 hours, then adjust subsequent doses depending on patient response and tolerability.
Child: ≥2 years Monotherapy: Patient weighing <50 kg: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on patient response and tolerability. ≥10 kg to <40 kg: Max: Up to 6 mg/kg bid. ≥40 kg to <50 kg: Max: 5 mg/kg bid. Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among countries (refer to specific product guidelines).
Child: ≥2 years Monotherapy: Patient weighing <50 kg: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on patient response and tolerability. ≥10 kg to <40 kg: Max: Up to 6 mg/kg bid. ≥40 kg to <50 kg: Max: 5 mg/kg bid. Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among countries (refer to specific product guidelines).
Intravenous
Primary generalised tonic-clonic seizures
Adult: Adjunctive therapy: Initially, 50 mg bid, increased to 100 mg bid after 1 week. Maintenance dose may be further increased in increments of 50 mg bid at weekly intervals depending on patient response and tolerability. Max: 200 mg bid. Treatment initiation with a loading dose: Initially, 200 mg as a single dose, followed by 100 mg bid after approx 12 hours, then adjust subsequent doses according to patient response and tolerability.
Child: ≥4 years weighing <50 kg: Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among countries (refer to specific product guidelines).
Child: ≥4 years weighing <50 kg: Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among countries (refer to specific product guidelines).
Oral
Primary generalised tonic-clonic seizures
Adult: Adjunctive therapy: Initially, 50 mg bid, increased to 100 mg bid after 1 week. Maintenance dose may be further increased in increments of 50 mg bid at weekly intervals depending on patient response and tolerability. Max: 200 mg bid. Treatment initiation with a loading dose: Initially, 200 mg as a single dose, followed by 100 mg bid after approx 12 hours, then adjust subsequent doses according to patient response and tolerability.
Child: ≥4 years weighing <50 kg: Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on the patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: ≥4 years weighing <50 kg: Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on the patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Oral
Partial seizures with or without secondary generalisation
Adult: Monotherapy: Initially, 50 mg bid, increased to 100 mg bid after 1 week. Alternatively, initial doses of 100 mg bid may be given. Increase doses in increments of 50 mg bid at weekly intervals depending on the patient response and tolerability. Max: 300 mg bid. Adjunctive therapy: Initially, 50 mg bid, increased to 100 mg bid after 1 week. Maintenance dose may be further increased in increments of 50 mg bid at weekly intervals depending on the patient response and tolerability. Max: 200 mg bid. Treatment initiation with a loading dose: Initially, 200 mg as a single dose, followed by 100 mg bid after approx 12 hours, then adjust subsequent doses depending on patient response and tolerability. Dosing recommendations may vary among countries (refer to specific product guidelines).
Child: ≥2 years Monotherapy: Patient weighing <50 kg: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on the patient response and tolerability. ≥10 kg to <40 kg: Max: Up to 6 mg/kg bid. ≥40 kg to <50 kg: Max: 5 mg/kg bid. Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on the patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among countries (refer to specific product guidelines).
Child: ≥2 years Monotherapy: Patient weighing <50 kg: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on the patient response and tolerability. ≥10 kg to <40 kg: Max: Up to 6 mg/kg bid. ≥40 kg to <50 kg: Max: 5 mg/kg bid. Adjunctive therapy: Initially, 1 mg/kg bid, increased to 2 mg/kg bid after 1 week. Maintenance dose may be further increased in increments of 1 mg/kg bid at weekly intervals depending on the patient response and tolerability. ≥10 kg to <20 kg: Max: Up to 6 mg/kg bid. ≥20 kg to <30 kg: Max: 5 mg/kg bid. ≥30 kg to <50 kg: Max: 4 mg/kg bid. ≥50 kg: Same as adult dose. Dosing recommendations may vary among countries (refer to specific product guidelines).
